29 septiembre 2014
The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/jNP1rZ5L8d4/140929090350.htm
